164 related articles for article (PubMed ID: 29362858)
1. Repeatability of quantitative
Kramer GM; Liu Y; de Langen AJ; Jansma EP; Trigonis I; Asselin MC; Jackson A; Kenny L; Aboagye EO; Hoekstra OS; Boellaard R;
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):951-961. PubMed ID: 29362858
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility and Repeatability of Semiquantitative
Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ
J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121
[No Abstract] [Full Text] [Related]
3. Repeatability of
Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
[TBL] [Abstract][Full Text] [Related]
4. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
5. Repeatability of Quantitative
Jansen BHE; Cysouw MCF; Vis AN; van Moorselaar RJA; Voortman J; Bodar YJL; Schober PR; Hendrikse NH; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2020 Sep; 61(9):1320-1325. PubMed ID: 31924729
[TBL] [Abstract][Full Text] [Related]
6. Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer.
Oprea-Lager DE; Kramer G; van de Ven PM; van den Eertwegh AJ; van Moorselaar RJ; Schober P; Hoekstra OS; Lammertsma AA; Boellaard R
J Nucl Med; 2016 May; 57(5):721-7. PubMed ID: 26697964
[TBL] [Abstract][Full Text] [Related]
7. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
8. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone.
Trigonis I; Koh PK; Taylor B; Tamal M; Ryder D; Earl M; Anton-Rodriguez J; Haslett K; Young H; Faivre-Finn C; Blackhall F; Jackson A; Asselin MC
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):682-93. PubMed ID: 24504503
[TBL] [Abstract][Full Text] [Related]
9. Baseline and longitudinal variability of normal tissue uptake values of [
Cysouw MCF; Kramer GM; Frings V; De Langen AJ; Wondergem MJ; Kenny LM; Aboagye EO; Kobe C; Wolf J; Hoekstra OS; Boellaard R
Nucl Med Biol; 2017 Aug; 51():18-24. PubMed ID: 28528264
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
11. Variability and Repeatability of Quantitative Uptake Metrics in
Zhuang M; García DV; Kramer GM; Frings V; Smit EF; Dierckx R; Hoekstra OS; Boellaard R
J Nucl Med; 2019 May; 60(5):600-607. PubMed ID: 30389824
[TBL] [Abstract][Full Text] [Related]
12. Repeatability of Quantitative 18F-NaF PET: A Multicenter Study.
Lin C; Bradshaw T; Perk T; Harmon S; Eickhoff J; Jallow N; Choyke PL; Dahut WL; Larson S; Humm JL; Perlman S; Apolo AB; Morris MJ; Liu G; Jeraj R
J Nucl Med; 2016 Dec; 57(12):1872-1879. PubMed ID: 27445292
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
14. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer.
Frings V; de Langen AJ; Smit EF; van Velden FH; Hoekstra OS; van Tinteren H; Boellaard R
J Nucl Med; 2010 Dec; 51(12):1870-7. PubMed ID: 21078791
[TBL] [Abstract][Full Text] [Related]
15. Test-Retest Repeatability of Patlak Slopes versus Standardized Uptake Values for Hypermetabolic Lesions and Normal Organs in an Oncologic PET/CT Population.
Ince S; Laforest R; Ashrafinia S; Smith AM; Wahl RL; Fraum TJ
Mol Imaging Biol; 2024 Apr; 26(2):284-293. PubMed ID: 38466523
[TBL] [Abstract][Full Text] [Related]
16. Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography.
de Langen AJ; Klabbers B; Lubberink M; Boellaard R; Spreeuwenberg MD; Slotman BJ; de Bree R; Smit EF; Hoekstra OS; Lammertsma AA
Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):389-95. PubMed ID: 18931838
[TBL] [Abstract][Full Text] [Related]
17. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
[TBL] [Abstract][Full Text] [Related]
18. Meta-Analysis of the Test-Retest Repeatability of [18F]-Fluorodeoxyglucose Standardized Uptake Values: Implications for Assessment of Tumor Response.
Shankar LK; Huang E; Litiere S; Hoekstra OS; Schwartz L; Collette S; Boellaard R; Bogaerts J; Seymour L; deVries EGE
Clin Cancer Res; 2023 Jan; 29(1):143-153. PubMed ID: 36302172
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
[TBL] [Abstract][Full Text] [Related]
20. High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with
Werner RA; Habacha B; Lütje S; Bundschuh L; Higuchi T; Hartrampf P; Serfling SE; Derlin T; Lapa C; Buck AK; Essler M; Pienta KJ; Eisenberger MA; Markowski MC; Shinehouse L; AbdAllah R; Salavati A; Lodge MA; Pomper MG; Gorin MA; Bundschuh RA; Rowe SP
Mol Imaging; 2022; 2022():7056983. PubMed ID: 35283693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
